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In Germany, mumps has been notifiable until 2013 
only in the five Eastern federal states (EFS) of former 
East Germany. Due to different immunisation policies 
until 1990 and varying vaccination coverages thereaf-
ter, mumps incidences cannot be extrapolated to the 
11 Western federal states (WFS). We studied mumps-
related International Classification of Diseases (ICD-
10) code diagnoses claimed through statutory health 
insurances between 2007 and 2011 to estimate coun-
trywide mumps incidences in the outpatient sector, 
and compared them with case numbers from ambu-
latory notification data. Overall, 32,330 outpatient 
mumps cases were claimed. Annual incidence ranged 
between 9.3/100,000 and 11.8/100,000 and showed 
a significant decreasing trend. Compared with EFS, 
mumps incidence in WFS was higher and indicated a 
shift towards older age groups. Notified outpatient 
case numbers in EFS were 13-fold lower and from vol-
untary surveillance during an outbreak in the WFS 
Bavaria 8-fold lower than from insurance data (n=316 
versus n=4,217 and n=238 versus 1,995, respectively). 
Of all notified cases with available information, 75.4% 
(EFS) and 57.6% (Bavaria) were unvaccinated; 6.8% 
(EFS) and 19.3% (Bavaria) required hospitalisation. In 
Germany, mumps is still endemic despite decades of 
vaccination, with considerable underreporting in the 
established notification systems.
Introduction 
Mumps is a vaccine-preventable viral disease, typi-
cally characterised by swelling of the parotid glands, 
but can also cause severe complications like orchitis, 
meningitis, encephalitis or pancreatitis [1,2]. The dis-
ease usually occurs among children and in the pre-
vaccine era, the annual reported mumps incidences in 
Western European countries ranged between 100 and 
600 per 100,000 inhabitants [3]. With the availability 
of a live-attenuated mumps vaccine since the 1960s 
[4], disease incidence dramatically decreased in coun-
tries with mumps vaccination programmes [5,6]. Over 
the past years, however, numerous reports from dif-
ferent countries with long-established vaccination pro-
grammes have been published about extensive mumps 
outbreaks that occurred predominantly among vacci-
nated children, adolescents, and young adults [7-15]. 
Until 2013, mumps has been notifiable in Germany 
only in the five Eastern federal states (EFS) of former 
East Germany. During the years 2001 to 2011, annually 
reported incidence for all EFS ranged between 0.26 
and 0.78/100,000 [16]. There was no mandatory noti-
fication system in place in the remaining 11 Western 
federal states (WFS) of former West Germany. However, 
if an outbreak occurs in an institutional setting, the 
‘German Infection Protection Act’ requires the institu-
tion to immediately inform the district health authority. 
A recent comprehensive survey suggested an increase 
in the number of mumps outbreaks over the past 10 
years [17]. The largest recorded outbreak occurred 
in the WFS of Bavaria in 2010/11. Voluntary (ad-hoc) 
reporting was set up during the outbreak period and 
identified 295 cases. 
Although mumps incidences have been available for 
EFS for the past 10 years, incidences cannot be extrap-
olated to the 11 WFS due to historical differences in 
vaccination schedules and coverage rates. While West 
Germany had recommended one dose of mumps vac-
cine as part of the routine childhood vaccination sched-
ule from 1976 onwards, East Germany had no mumps 
vaccination programme in place until reunification in 
1990. Since 1991, two doses (in the second and sixth 
year of life) have been recommended throughout the 
reunified Germany, since 2001 with the first dose given 
at 11–14 months and the second dose at 15–23 months 
of age [18]; the vaccine strain predominantly used is 
Jeryl Lynn. Although routine mumps vaccination was 
adopted in EFS 15 years later than in WFS, vaccination 
coverage rates at school entry have been substantially 
higher in EFS since introduction of coverage monitoring 
in 1998 (Figure 1) [19]. 
In the absence of a countrywide mandatory mumps 
notification requirement until March 2013 we used 
billing data of the Associations of Statutory Health 
Insurance Physicians (ASHIP) for outpatients as an 
alternative data source. Approximately 85% of the 
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population living in Germany is covered by statutory 
health insurances (total population in Germany in 2011: 
81.8 million; WFS: 69.0 million, EFS: 12.8 million), and 
mumps is a disease usually treated on an outpatient 
basis (in EFS 2001–11: 94%). The aim of our study was 
to use countrywide ASHIP data (i) to estimate ambu-
latory mumps incidences and describe mumps-related 
demographics countrywide and separately for EFS and 
WFS, (ii) to estimate incidence and describe demo-
graphics for the outbreak in Bavaria 2010/11, and (iii) 
to compare the number of cases and demographics 
identified in the ambulatory ASHIP dataset with corre-
sponding figures from the mandatory notification sys-




For ASHIP data, a mumps case was defined as a per-
son diagnosed with a mumps-related International 
Classification of Diseases (ICD-10) code (B26.0-
orchitis, B26.1-meningitis, B26.2-encephalitis, B26.3-
pancreatitis, B26.8-‘other complication’, B26.9-‘no 
complication’), and for notification data as a person 
fulfilling the mumps case definition (clinical case, i.e. 
more than two days of one- or two-sided parotidal 
swelling without any other apparent cause, and/or clin-
ical case with epidemiological link and/or clinical case 
with laboratory confirmation) [20]. Incidence based on 
ASHIP data was defined as number of outpatient cases 
per 100,000 statutory health-insured [21], whereas 
incidence based on the mandatory notification system 
was defined as number of outpatient cases per 100,000 
inhabitants in Germany [22]. The German federal states 
of Brandenburg, Mecklenburg-Western Pomerania, 
Saxony, Saxony-Anhalt, and Thuringia were classified 
as EFS; Baden-Württemberg, Bavaria, Berlin (com-
prising of the former Eastern and Western part of the 
city), Bremen, Hamburg, Hesse, Lower Saxony, North 
Rhine-Westphalia, Rhineland-Palatinate, Saarland, 
Schleswig-Holstein as WFS. The Bavarian outbreak 
period ranged from the third quarter of 2010 to the sec-
ond quarter of 2011, the non-outbreak period were the 
remaining quarters in the years 2007 to 2011.
ASHIP data structure and data 
included in the analysis
Statutory health insurance physicians send their 
reimbursement claims for provided ambulatory medi-
cal services, based on the ICD-10 code, to their cor-
responding regional ASHIP on a quarterly basis. Our 
dataset included the patient’s anonymous unique 
identifier (ID), sex, month/year of birth, district/state 
of residence, state of billing physician’s practice, ICD-
10 code, quarter/year of diagnosis, reliability of diag-
nosis (suspected, confirmed, excluded or recovered), 
and type of diagnosis (current state, previous state, 
unknown or not provided). 
Figure 1
Mumps vaccination coverage rates for first and second dose at school entry (age 5–7 years) in Western and Eastern federal 
states, Germany, 1998–2010
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Our analysis contained mumps diagnoses billed 
between 1 January 2007 and 31 December 2011. Data 
from the states of Baden-Württemberg (2007 only) and 
Hesse (2007–11) had to be excluded due to incomplete 
information. After the exclusion, the data set covered 
79% of the population living in Germany during 2008 
to 2011 and 68% during 2007. 
ASHIP data cleaning
We only included confirmed diagnoses that were 
labelled as ‘current state’ for the calculation of inci-
dences. To limit the dataset to a single diagnosis per 
unique ID, we used the following algorithm:
1.  Exclusion of incompatible or implausible coding 
combinations of ‘reliability of diagnosis’ (e.g. all 
four options coded in the same quarter);
2.  Exclusion of observations coded as suspected, 
excluded or recovered (‘reliability of diagnosis’);
3.  Exclusion of observations coded as previous state, 
unknown or not provided (‘type of diagnosis’);
4.  Limitation to the most severe ICD-10 code diagnosed 
at the earliest point in time (one observation per 
unique ID), using the following ranking (from most 
to least severe): encephalitis>meningitis>orchitis>p
ancreatitis>other complication>no complication.
For data from Bavaria, Rhineland-Palatinate (2007–11) 
and regional parts of North Rhine-Westphalia (2008–
11), step 3 had to be omitted as the transmitted data 
did not routinely contain information on ‘type of 
diagnosis’.
Mandatory and ad-hoc notification data
We retrieved mandatory mumps notification data 
reported from EFS through the German electronic sur-
veillance system ‘SurvNet’ [23] that is routinely used by 
public health authorities to anonymously report infor-
mation on inpatient and outpatient cases with notifia-
ble diseases to the national level. The ‘SurvNet’ system 
was also used by district health authorities for the vol-
untary ad-hoc mumps reporting during the outbreak in 
Bavaria 2010/11. Notification datasets contained infor-
mation on age, sex, date of disease onset, notification 
week, district/state of residence, vaccination status, 
and whether the case required hospitalisation.
Statistical analysis
We used chi-square test to test differences in inci-
dences and proportions and Poisson regression to 
determine trends in incidence rate ratios (IRR). P val-
ues were defined as statistically significant if <0.05. 
Statistical analysis was performed by using Stata ver-
sion 12.1 (StataCorp, Texas, US).
Results
Cleaning of ASHIP data
A total of 137,087 mumps diagnoses were billed during 
2007 to 2011 (Bavaria, Rhineland-Palatinate and parts 
of North Rhine-Westphalia: 47,165; remaining included 
states: 89,922). In data cleaning step 1, the number of 
diagnoses decreased to 136,142 (46,728 and 89,414), 
in step 2 to 49,746 (16,516 and 33,230), and in step 3 
to 40,819 (16,516 (not applicable) and 24,303). Step 4 
limited the dataset to 32,330 confirmed mumps cases 
(11,330 and 21,000). Among the 86,396 diagnoses 
excluded in step 2, 36,957 (42.8%) observations were 
coded as suspected diagnoses that would, if included 
in the dataset, have accounted for an additional 29,514 
suspected mumps cases after steps 3 and 4 (10,406 
and 19,108).
Estimation of countrywide and regional 
incidences based on ASHIP data
Of the 32,330 confirmed cases, 15,000 (46.4%) were 
male; for 212 (0.7%) no sex was specified. For the years 
2007 to 2011, overall countrywide mumps incidence 
was 10.3/100,000 and ranged between 9.3/100,000 in 
2010 and 11.8/100,000 in 2008, corresponding to an 
IRR of 0.95 (95% confidence interval (CI): 0.95–0.96; 
p<0.005). The most affected age groups in 2007 to 2011 
were children aged five to nine years (mean annual 
incidence: 20.7/100,000) and adolescents aged 15 to 19 
years (17.9/100,000). The most common complication 
was orchitis (n=933; 6.2% of male cases), followed by 
‘other complication’ (n=581; 1.8%), meningitis (n=141; 
0.4%), pancreatitis (n=92; 0.3%), and encephalitis 
(n=61; 0.2%). Except for orchitis, proportions of com-
plications showed no statistically significant difference 
between sexes. The proportion of complications among 
cases 15 years and older was significantly higher for 
all entities than among cases younger than 15 years 
(orchitis: 7.9% versus 1.8% among male cases; ‘other 
complication’: 1.9% versus 1.3%; meningitis: 0.5% ver-
sus 0.2%; pancreatitis: 0.3% versus 0.1%; encephali-
tis: 0.2% versus 0.0%; p<0.005 for all). 
Mean annual mumps incidence in 2007 to 2011 was sig-
nificantly higher in WFS than in EFS (10.9/100,000 ver-
sus 7.5/100,000; p<0.005). Incidences ranged between 
7.0 and 8.4/100,000 in EFS, with a significant declining 
trend over the five years under observation (IRR=0.95; 
95% CI: 0.93–0.97; p<0.005), and between 9.8 and 
12.6/100,000 in WFS (IRR=0.96; 95% CI: 0.95–0.96; 
p<0.005). Stratification by age group showed a signifi-
cant decreasing trend for incidences in the under 20 
year-olds in EFS. In the WFS, incidences significantly 
decreased in the age groups of under 20 year-olds 
and of those aged 40 years and older, but significantly 
increased in the 20 to 29 year-olds (Table). The mean 
annual incidence of orchitis was higher in WFS than in 
EFS (0.72/100,000 versus 0.12/100,000 male cases; 
p<0.005). The proportion of orchitis complications 
among male cases by age group and geographic region 
is displayed in Figure 2.
Description of the 2010/11 outbreak 
in Bavaria based on ASHIP data
Between 2007 and 2011, Bavarian physicians billed 
6,111 confirmed outpatient mumps cases to the 
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Table 
Annual mumps incidence, incidence rate ratio and p value, by age group, based on ambulatory statutory health insurance 
claims data, Germany, 2007–2011 (n=32,330)
Age group 
(years) 2007 2008 2009 2010 2011 IRR 95% CI p value
Western federal states 
<10 22.7 23.3 16.8 15.4 14.7 0.87 0.86–0.90 <0.005
10–19 19.3 20.7 15.2 15.3 18.4 0.96 0.94–0.98 <0.005
20–29 12.6 16.8 12.3 16.0 17.2 1.06 1.03–1.08 <0.005
30–39 9.9 11.9 9.8 9.4 11.0 1.00 0.97–1.02 0.707
40–49 8.8 9.7 8.4 7.1 8.3 0.96 0.93–0.98 <0.005
≥50 8.3 7.9 7.5 6.4 6.6 0.93 0.92–0.95 <0.005
Eastern federal states  
<10 19.4 17.1 13.6 13.0 9.9 0.85 0.81–0.90 <0.005
10–19 15.9 18.1 12.5 11.4 10.1 0.88 0.83–0.93 <0.005
20–29 9.1 9.7 8.6 7.4 8.7 0.96 0.91–1.02 0.208
30–39 6.6 9.2 7.7 7.5 8.3 1.02 0.96–1.09 0.486
40–49 7.0 7.7 6.6 6.9 7.5 1.00 0.95–1.06 0.867
≥50 5.5 5.2 4.9 5.2 5.2 0.99 0.95–1.03 0.527
CI: confidence interval; IRR: incidence rate ratios. 
Significant IRR, 95%CI and p values are shown in bold.
Figure 2
Mean annual mumps incidence among males and proportion of mumps-associated orchitis among all male mumps cases 
per age group, based on ambulatory statutory health insurance claims data, Germany 2007–2011 
EFS: Eastern federal states; WFS: Western federal states.
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statutory health insurances. Of those, 1,995 (32.6%) 
were claimed during the outbreak period with the peak 
occurring in the first quarter of 2011 (n=752; 37.7%). 
The proportion of claimed male cases was higher 
during the outbreak period than in the non-outbreak 
period (52.0% versus 47.5%; p<0.005), and a compari-
son of age-specific incidences indicated that the out-
break affected mainly the age group of 15–34 year-olds 
(Figure 3). Furthermore, the proportion of orchitis com-
plications was significantly higher during the outbreak 
period compared to the non-outbreak period (17.7% 
versus 11.7%; p<0.005); all other proportions of com-
plications showed no significant differences (data not 
shown). 
EFS: Comparison of ASHIP data with 
mandatory notification data
In EFS, physicians claimed 4,217 confirmed outpatient 
mumps cases during 2007 to 2011 through the statu-
tory health insurances. The median age of claimed 
cases was 38 years, and 1,825 (43.3%) were male. In 
the same time period, 316 ambulatory and 23 cases 
that required hospitalisation were reported via the 
mandatory notification system. The median age of the 
reported 316 outpatient cases was 12 years, and 148 
(46.8%) were male. In total, 13.3 times more insurance 
cases were claimed than reported via the mandatory 
notification system. Stratified by age, 3,048 claimed 
ambulatory cases were adults (≥20 years) compared 
to 113 notified ambulatory cases (27.0-fold difference); 
among persons younger than 20 years, the difference 
was 5.8-fold (1,169 claimed versus 203 notified cases). 
Vaccination status was available for 284 (83.8%) of the 
339 cases from the notification system: 214 (75.4%) 
were unvaccinated, whereas 70 (24.6%) had received 
at least one vaccination (33 received one dose, 36 
received two doses, and one received four doses). 
Vaccination status by age group is shown in Figure 4. 
Bavarian outbreak 2010/11: Comparison of 
ASHIP data with ad-hoc notification data
Temporary voluntary notification during the mumps 
outbreak in Bavaria identified 238 ambulatory cases 
and 57 cases requiring hospitalisation. Of the ambu-
latory cases, 124 (52.1%) were male. The median age 
was 21 years versus 24 years in ASHIP data. In com-
parison to ASHIP data (n=1,995), there was an 8.3-
fold difference to ad-hoc reporting. Stratified by age, 
107 reported ambulatory cases were younger than 20 
years, compared with 594 outpatient cases claimed in 
insurance data (a 5.6-fold difference); in the group 20 
years and older, 131 cases were reported, in contrast 
to 1,401 cases from ASHIP data (a 10.7-fold differ-
ence). Vaccination status was available for 217 of 295 
(73.6%) reported cases: 125 (57.6%) were unvaccinated 
and 92 (42.4%) had received at least one vaccination 
(38 received one dose, 53 received two doses and one 
received three doses); for vaccination status per age 
group see Figure 5.
Discussion
Because countrywide mandatory mumps notification 
was not in place until 2013, we used mumps-related 
ICD-10 code diagnoses claimed through statutory 
Figure 3
Title: Mumps incidence per age group based on ambulatory statutory health insurance claims data during the 2010/11 
outbreak period (n=1,995) and non-outbreak period (n=4,116), Bavaria, 2007–2011

























health insurances to estimate the magnitude of mumps 
incidence in Germany. Our results demonstrate that 
mumps is still endemic in Germany despite long-estab-
lished vaccination programmes. However, overall inci-
dences have dramatically declined from an estimated 
100 to 1,000 cases per 100,000 in the pre-vaccine era 
[24] to 10.3 per 100,000 in the time period from 2007 
to 2011. Moreover, incidences showed a further slight 
but statistically significant decreasing trend during the 
five-year study period, although incidence patterns 
across age groups differed in WFS and EFS. This dis-
crepancy can be explained by different dates of mumps 
vaccine introduction and different vaccination cover-
ages in the following years. 
In the absence of a mumps vaccination programme 
in EFS until 1991, a great proportion of the EFS-
population born before 1990 is likely to have been 
exposed to the wild virus and to have acquired natu-
ral immunity during childhood, consistent with the 
considerably lower incidences in adults in EFS com-
pared with WFS, especially in the age group of 20 to 
29 year-olds. Serosurveys from European countries in 
the pre-vaccine era have shown that 90% of the popu-
lation was seropositive by the age of 14 to 15 years [4]. 
Because routine mumps vaccination was introduced 
in the WFS in 1976, high prevalence rates of naturally 
acquired immunity are only found in those who were 
born in 1975 and later (in our dataset 32 to 36 years 
and older). During 1976–90, the WFS recommended 
one mumps vaccine dose, but comprehensive data on 
coverage rates from that period are not available. The 
two-dose mumps recommendation, introduced in WFS 
and EFS in 1991, has only targeted children born after 
1990 (in our dataset 17 to 21 years and younger). The 
significant incidence differences in individuals younger 
than 20 years as well as the significant decreasing 
trend over the study period correspond to increasing 
vaccination coverages seen at school entry in both 
EFS and WFS. However, two-dose coverage in EFS has 
been substantially higher since beginning of monitor-
ing. Although two-dose vaccination coverage rates are 
approaching levels to reach herd immunity of at least 
92% [25] in both parts of the country, previous lower 
rates and a lack of catch-up vaccination activities may 
have left a pool of susceptibles that account for the 
high incidences in children and young adults. A repre-
sentative seroprevalence study, conducted in 2003 to 
2006 among more than 13,000 individuals aged 0 to 
17 years in Germany, revealed approximately 20–22% 
to be mumps IgG-negative or borderline-positive, with 
higher proportions in the WFS [26]. However, if the pre-
sent high vaccination coverage at school entry can be 
sustained, incidences among children can be expected 
to further decrease.
In contrast to EFS, we observed in WFS a significant 
increasing incidence trend among 20 to 29 year-olds, 
suggesting an age-shift over time. This observation is 
mirrored by the Bavarian outbreak 2010/11 where high-
est incidences were seen among 15 to 29 year-olds; the 
finding is further in line with recent outbreak reports 
from other countries with long-established vaccina-
tion programmes [10-13,15]. One reason could be that 
Figure 4
Vaccination status per age group among mumps cases with known status, reported via the mandatory notification system, 
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suboptimal vaccination coverage rates combined with 
low circulation of wild virus have caused an accumula-
tion of susceptibles in those age groups. This theory is 
supported by the German serosurvey [26], but also by 
86,098 immunisation records from 10 to 12 year-olds in 
Bavaria in 1988 (born one to three years after adoption 
of mumps vaccination) that revealed mumps coverage 
rates of only 55% [27]. Another relevant factor could 
be waning immunity. In the same serosurvey, authors 
identified significant waning effects already in 0 to 17 
year-old immunised children [26], and those effects 
could be even more dominant in older age groups with 
longer time spans since last vaccination and/or only 
one vaccination dose. Furthermore, the proportion of 
vaccinated cases in the Bavarian outbreak increased 
with age in the group of 15 to 29 year-olds. Although 
we only had vaccination status information for 217 
reported cases, age and sex distribution were compa-
rable with findings from ASHIP data. The results could 
therefore be a hint that waning immunity may indeed 
play a role in those age groups in Germany. In contrast, 
breakthrough infections were not observed among 
young adult cases in EFS; all breakthrough infections 
occurred among children and adolescents and could 
therefore reflect the expected proportion of vaccine 
failure in populations with high vaccination coverage. 
Mumps incidences for Germany based on ASHIP data 
are substantially higher than incidences for Europe pub-
lished by the European Centre for Disease Prevention 
and Control: 3.5 per 100,000 in 2010 [28] and 3.2 per 
100,000 in 2009 [29]. However, the 27 countries differ 
in their mumps surveillance systems, case definitions 
and time points of routine mumps vaccine introduction 
[30,31], and comparisons are therefore difficult. 
Comparison of the mandatory notification data with 
ASHIP data in EFS indicated severe underreporting, 
especially among adults. Underreporting could even 
be higher, as we only included cases coded as con-
firmed and diagnosed in an ambulatory practice. Our 
findings suggest that in EFS, where mandatory mumps 
surveillance has been in place since 1964 [24], physi-
cians diagnose mumps, but fail to report cases to pub-
lic health authorities. This has important implications 
as Germany has introduced nationwide mandatory 
reporting of mumps as of March 2013. To retain reli-
able mumps notification data, it is crucial not only to 
(re)inform physicians about their reporting duty, but to 
think of new strategies to ease reporting. One approach 
could be to develop computer tools that directly link 
the ICD coding of notifiable infectious diseases with a 
report to the health authorities. 
There is an increasing use of electronic health records 
or claims data to estimate disease trends or disease 
burden, especially for admission or discharge ICD 
codes from hospitals, e.g. for rotavirus, gonorrhoea, or 
varicella [32-34]. In Germany, ICD-10 codes have previ-
ously been used to assess the herpes zoster disease 
burden also in the outpatient sector [35], and to assess 
reporting completeness of notifiable disease surveil-
lance systems [36,37]. However, electronic health 
records or claims data cannot and should not replace a 
surveillance system, as the data are usually only avail-
able with a time lag of several months, precluding rapid 
containment actions in the event of an outbreak, and 
Figure 5
Vaccination status per age group among mumps cases with known status, reported via the voluntary ad-hoc notification 
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are primarily intended for documentation or reimburse-
ment, not surveillance purposes. In the case of ASHIP 
data, important information such as vaccination sta-
tus at diagnosis or required hospitalisation is lacking. 
Nevertheless, such data can be an important source 
to assess the magnitude of incidences, disease trends 
and underreporting, and their reliability to determine 
communicable disease trends and burden should be 
further explored, also for the outpatient sector. 
Using ASHIP data to estimate mumps incidences had 
several limitations related to data structure. There are 
no standardised guidelines for physicians of when to 
code a case as suspected or confirmed. Aiming at a 
conservative estimate, we decided to only include con-
firmed diagnoses. This restriction, as well as limiting 
the dataset to one observation per patient (who may 
have had several physician consultations during one 
disease episode), reduced the initial dataset consider-
ably during the cleaning process. Therefore, the extent 
of the reduction cannot be interpreted as an indicator 
for the ASHIP data quality per se. As laboratory con-
firmation is not required to code a case as confirmed, 
the proportion of laboratory confirmations is unknown. 
Moreover, ASHIP data only cover ambulatory cases. 
However, since mumps has a very distinct clinical 
presentation and the vast majority of mumps patients 
remain outpatients or have consulted their ambulatory 
physician before complications may require hospitali-
sation, it can be assumed that our incidence estimates 
are a good reflection of the true disease incidence. 
Our dataset did not include the ca. 15% of the popula-
tion with private health insurance. However, we used 
the ASHIP population as denominator to calculate 
incidences and do not expect that mumps vaccination 
coverage differs substantially between privately and 
statutory insured. Finally, as information on ‘type of 
diagnosis’ is routinely missing for Bavaria, Rhineland-
Palatinate and parts of North Rhine-Westphalia, we 
could not exclude diagnoses coded as ‘previous state’, 
‘unknown’ or ‘not provided’ in the data cleaning pro-
cess. However, if proportions of reduction had been 
applied to these federal states as observed for the oth-
ers (step 3: 26.9%; step 4: 13.6%), the total number of 
cases would have been reduced by only 899 (2.7%). 
Conclusions
ASHIP data proved a valuable alternative data source 
to estimate mumps incidences. The identified shift in 
age distribution, the vaccination status of reported 
cases, and serosurveys indicate that inadequate cover-
age (with less than two mumps vaccine doses) is the 
main reason for outbreaks und sustained mumps virus 
circulation in Germany. In 2010, the German Standing 
Committee on Vaccination (STIKO) recommended an 
additional MMR vaccination for persons born after 1970 
with less than two measles vaccinations in their child-
hood [18], a recommendation that may simultaneously 
close some of the existing mumps vaccination gaps 
in adults. However, no catch-up vaccination activities 
for mumps have been initiated so far. In view of recent 
mumps outbreaks among adolescents and young 
adults and indications of waning immunity, the option 
of a third routine mumps vaccine dose is being dis-
cussed in the scientific literature [10,14,38]. However, 
comprehensive data on the long-term effectiveness of 
two-dose mumps vaccination (e.g. measured during 
outbreaks among adolescents and young adults) and 
on the additional benefits of a third dose are lacking. 
For the youngest age groups, efforts should focus on 
sustaining and even increasing the existing high vac-
cination coverage. In this respect, Finland has set an 
important example of how to successfully eliminate 
mumps by reaching and maintaining vaccination cover-
ages of more than 95% [39].
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